Letter

Drug eluting stents

What fuels public policy?

BMJ 2007; 334 doi: 10.1136/bmj.39150.648762.BE (Published 22 March 2007)
Cite this as: BMJ 2007;334:599.4

This article has a correction

Please see: Drug eluting stents: What fuels public policy?

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Mark H Wilson, director of medical ethics health (research@sympatico.ca)
  1. Health Research Associates, Ottawa, Canada K2B 6J4

    Around 60-75% of the millions of drug eluting stents inserted globally are not licensed.1 What has fuelled the high unlicensed use of a device associated with thrombosis? This question was not dealt with by the Food and Drug Administration panel or recent articles on such stents.2 …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular